cancer vaccines

Moderna and Merck’s mRNA Cancer Vaccine Impresses but Experts Urge Caution
Moderna and Merck’s mRNA Cancer Vaccine Impresses but Experts Urge Caution
BioSpace
Moderna Therapeutics
Merck
MRNA
cancer vaccines
vaccines
Flag link:
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Biopharma Reporter
Merck
Moderna Therapeutics
cancer
cancer vaccines
Keytruda
clinical trials
Flag link:
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine
BioSpace
Moderna Therapeutics
MRNA
vaccines
cancer
cancer vaccines
Flag link:
Moderna's Cancer Vaccine Wins An FDA Boon, But Shares Drop On Mixed Earnings
Moderna's Cancer Vaccine Wins An FDA Boon, But Shares Drop On Mixed Earnings
Investors Business Daily
Moderna Therapeutics
earnings
MRNA
vaccines
FDA
cancer vaccines
Flag link:
BioNTech touts differences with Moderna in race for cancer vaccines
BioNTech touts differences with Moderna in race for cancer vaccines
Endpoints
BioNTech
Moderna Therapeutics
Merck
vaccines
cancer
cancer vaccines
Flag link:
Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move
Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move
Fierce Biotech
Elicio Therapeutics
NASDAQ
cancer vaccines
clinical trials
Angion Biomedica
Flag link:
Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony
Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony
Financial Times
vaccines
Moderna Therapeutics
BioNTech
MRNA
cancer vaccines
Flag link:
mRNA's Next Act: Cancer Vaccines and Gene Editing
mRNA's Next Act: Cancer Vaccines and Gene Editing
BioSpace
MRNA
vaccines
cancer vaccines
gene editing
Flag link:
ASCO: BioNTech's Roche-partnered cancer vaccine combo hints at survival benefit in prostate cancer
ASCO: BioNTech's Roche-partnered cancer vaccine combo hints at survival benefit in prostate cancer
Fierce Biotech
ASCO 2022
BioNTech
Roche
vaccines
cancer vaccines
pancreatic cancer
Flag link:
BioNTech takes its first cancer vaccine into phase 2
BioNTech takes its first cancer vaccine into phase 2
Pharmaforum
BioNTech
vaccines
cancer vaccines
clinical trials
BNT111
Flag link:
Here Are the Most Exciting Vaccines in Moderna's Pipeline
Here Are the Most Exciting Vaccines in Moderna's Pipeline
Motley Fool
Moderna Therapeutics
vaccines
cancer vaccines
COVID-19
CMV
Flag link:
Inovio’s reinvention falls flat
Inovio’s reinvention falls flat
EP Vantage
Inovio
VGX-3100
cancer vaccines
cancer
Flag link:
The Future of Cancer Treatment Lies in Vaccines, Say These Pioneers
The Future of Cancer Treatment Lies in Vaccines, Say These Pioneers
BioSpace
cancer
oncology
vaccines
cancer vaccines
Neuvogen
Lineage Therapeutics
BioNTech
Flag link:
IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines
IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines
Fierce Biotech
IO Biotech
IDO
PD-L1
vaccines
cancer vaccines
clinical trials
Flag link:
Biotech startup raises $25M for cancer, Covid-19 vaccines
Biotech startup raises $25M for cancer, Covid-19 vaccines
MedCity News
Aivita Biomedical
vaccines
COVID-19
cancer vaccines
Flag link:
JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies
JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies
Fierce Biotech
JPMHC 2021
Boehringer Ingelheim
Enara Bio
dark antigens
cancer
cancer vaccines
Flag link:
A cancer vaccine that might work? Moderna posts 'promising' early snapshot for Merck-partnered program and raids Bristol Myers for a new cancer R&D chief
A cancer vaccine that might work? Moderna posts 'promising' early snapshot for Merck-partnered program and raids Bristol Myers for a new cancer R&D chief
Endpoints
Moderna Therapeutics
MRNA
vaccines
cancer vaccines
mRNA-4157
Bristol-Myers Squibb
Flag link:
Pfizer Q3 cull sees midstage fast-tracked NASH drug axed, with a cancer vaccine and arthritis asset also chopped
Pfizer Q3 cull sees midstage fast-tracked NASH drug axed, with a cancer vaccine and arthritis asset also chopped
Fierce Pharma
Pfizer
earnings
NASH
arthritis
cancer vaccines
Flag link:
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Fierce Biotech
Genentech
Vaccibody
cancer
vaccines
Roche
cancer vaccines
Flag link:
Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test
Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test
Endpoints
MaxiVAX
cancer
vaccines
cancer vaccines
solid tumors
head and neck cancer
Flag link:

Pages